1IB

N-ethyl-3-fluoranyl-3-[3-fluoranyl-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide

Created:	2021-06-24
Last modified:	2022-10-26

Find Related PDB Entry
1 entries where 1IB is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	47
Chiral Atom Count	0
Bond Count	49
Aromatic Bond Count	6

2D diagram of 1IB

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	N-ethyl-3-fluoranyl-3-[3-fluoranyl-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide
Systematic Name (OpenEye OEToolkits)	~{N}-ethyl-3-fluoranyl-3-[3-fluoranyl-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide
Formula	C₁₈ H₂₄ F₂ N₂ O
Molecular Weight	322.393
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	CCNC(=O)[CH]1C[C](F)(C1)c2ccc(CN3CCCC3)c(F)c2
SMILES	OpenEye OEToolkits	2.0.7	CCNC(=O)C1CC(C1)(c2ccc(c(c2)F)CN3CCCC3)F
Canonical SMILES	CACTVS	3.385	CCNC(=O)[C@@H]1C[C@@](F)(C1)c2ccc(CN3CCCC3)c(F)c2
Canonical SMILES	OpenEye OEToolkits	2.0.7	CCNC(=O)C1CC(C1)(c2ccc(c(c2)F)CN3CCCC3)F
InChI	InChI	1.03	InChI=1S/C18H24F2N2O/c1-2-21-17(23)14-10-18(20,11-14)15-6-5-13(16(19)9-15)12-22-7-3-4-8-22/h5-6,9,14H,2-4,7-8,10-12H2,1H3,(H,21,23)/t14-,18-
InChIKey	InChI	1.03	SXMBKHYDZOCBMT-PPUGGXLSSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB12201
Name	PF-03654746
Groups	investigational
Description	PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.
Synonyms	PF-03654746
Categories	Cycloparaffins Histamine H3 Antagonists
CAS number	935840-31-6

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.